ATXI 1.99 Avenue Therapeutics, Inc.
| Range: | 1.7-45.0 | Vol Avg: | 47925 | Last Div: | 0 | Changes: | 0.11 |
| Beta: | -0.18 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Tue Jun 27 2017 | Empoloyees: | 3 | ||
| CUSIP: | 05360L205 | CIK: | 0001644963 | ISIN: | US05360L3042 | Country: | US |
| CEO: | Dr. Alexandra MacLean M.D. | Website: | https://www.avenuetx.com | ||||
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Stock Details
ATXI 12
Avenue Therapeutics (ATXI) PT Lowered to $12 at Maxim Group
Jason McCarthy·Fri Jun 07 2024
Maxim Group
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow